Thermo Fisher Scientific Inc. $TMO Shares Sold by Adage Capital Partners GP L.L.C.

Key Points

• Adage Capital Partners GP L.L.C. reduced its stake in Thermo Fisher Scientific by 40.2% during the first quarter, selling 156,863 shares, and now holds approximately 0.06% of the company.
• Despite the drop from Adage Capital, other hedge funds like Brighton Jones LLC and Revolve Wealth Partners LLC increased their positions in Thermo Fisher during the fourth quarter, reflecting overall positive sentiment among institutional investors.
• Thermo Fisher Scientific's latest earnings report showed a 2.9% year-over-year increase in revenue, with an EPS of $5.36, exceeding analyst expectations and demonstrating the company's ongoing financial strength.

Adage Capital Partners GP L.L.C. reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 40.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 233,452 shares of the medical research company's stock after selling 156,863 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 0.06% of Thermo Fisher Scientific worth $116,166,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Mondrian Investment Partners LTD lifted its stake in shares of Thermo Fisher Scientific by 146.1% in the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after buying an additional 127,357 shares in the last quarter. GAMMA Investing LLC raised its stake in Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after purchasing an additional 877 shares during the period. Deutsche Bank AG raised its stake in Thermo Fisher Scientific by 9.5% during the fourth quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after purchasing an additional 114,277 shares during the period. Cetera Trust Company N.A raised its stake in Thermo Fisher Scientific by 3.3% during the first quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock worth $2,312,000 after purchasing an additional 150 shares during the period. Finally, Philip James Wealth Mangement LLC purchased a new position in Thermo Fisher Scientific during the first quarter worth about $268,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 1.0%

Shares of TMO stock traded up $4.94 during trading on Thursday, reaching $489.49. The company's stock had a trading volume of 1,404,235 shares, compared to its average volume of 1,629,226. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market capitalization of $184.84 billion, a price-to-earnings ratio of 28.31, a P/E/G ratio of 2.59 and a beta of 0.75. The stock's 50-day moving average price is $459.03 and its 200 day moving average price is $453.64. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 9.95%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,666 shares of company stock worth $13,982,763. Corporate insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on TMO shares. Barclays lifted their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research note on Friday, July 11th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, August 18th. They set an "outperform" rating on the stock. Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Finally, Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $589.38.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.